Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT

Peter J McCartney,1,2 Hany Eteiba,1,2 Annette M Maznyczka,1,2 Margaret McEntegart,1,2 John P Greenwood,3 Douglas F Muir,4 Saqib Chowdhary,5 Anthony H Gershlick,6 Clare Appleby,7 James M Cotton,8 Andrew Wragg,9 Nick Curzen,10 Keith G Oldroyd,2 Mitchell Lindsay,2 J Paul Rocchiccioli,2 Aadil Shaukat,2 Richard Good,2 Stuart Watkins,2 Keith Robertson,2 Christopher Malkin,3 Lynn Martin,2 Lynsey Gillespie,11 Thomas J Ford,1 Mark C Petrie,1,2 Peter W Macfarlane,12 R Campbell Tait,13 Paul Welsh,1 Naveed Sattar,1 Robin A Weir,14 Keith A Fox,15 Ian Ford,16 Alex McConnachie16 and Colin Berry1,2 on behalf of the T-TIME group

1British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
2West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UK
3Leeds University and Leeds Teaching Hospitals NHS Trust, Leeds, UK
4The James Cook University Hospital, South Tees Hospitals NHS Trust, Middlesbrough, UK
5Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
6University Hospitals of Leicester NHS Trust, Leicester, UK
7Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK
8Royal Wolverhampton NHS Trust, Wolverhampton, UK
9Barts Health NHS Trust and The Royal London Hospital, London, UK
10University Hospital Southampton Foundation Trust, Southampton, UK
11NHS Greater Glasgow and Clyde Board, Glasgow, UK
12Electrocardiography Core Laboratory, Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
13Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK
14University Hospital Hairmyres, NHS Lanarkshire, East Kilbride, UK
15College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK
16Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

*Corresponding author colin.berry@glasgow.ac.uk
Declared competing interests of authors: Annette M Maznyczka has received a British Heart Foundation (London, UK) Clinical PhD Fellowship (FS/16/74/32573). James M Cotton has received speaker honoraria from Abbott Vascular (Lake Bluff, IL, USA). Nick Curzen has received an unrestricted research grant and personal fees for lectures and consultancy from Abbott Vascular and Boston Scientific (Marlborough, MA, USA). R Campbell Tait has received personal fees and non-financial support from Bayer Healthcare (Leverkusen, Germany), personal fees from Pfizer Inc. (New York, NY, USA) and Shire Plc (Lexington, MA, USA), personal fees and non-financial support from Novo Nordisk A/S (Bagsværd, Denmark), personal fees from Sanofi SA (Paris, France), personal fees from Swedish Orphan Biovitrum (Stockholm, Sweden) and non-financial support from CSL Behring (King of Prussia, PA, USA). Paul Welsh has received grants from Boehringer Ingelheim (Ingelheim am Rhein, Germany) and Roche Holding AG (Basel, Switzerland) outside the submitted work. Naveed Sattar has received grants and personal fees from Boehringer Ingelheim, personal fees from Amgen Inc. (Thousand Oaks, CA, USA), AstraZeneca PLC (Cambridge, UK), Eli Lilly and Company (Indianapolis, IN, USA), Janssen Pharmaceutica (Beerse, Belgium), Novo Nordisk A/S and Sanofi SA. Keith A Fox has received grants and personal fees from Bayer/Janssen, grants from AstraZeneca and personal fees from Sanofi/Regeneron Pharmaceuticals (Tarrytown, NY, USA) and Verseon Corporation (Fremont, CA, USA). Colin Berry, based on contracts with the University of Glasgow, has held research and/or consultancy agreements with, and has received grants, non-financial support or other support from, Abbott Vascular, AstraZeneca, Boehringer Ingelheim, HeartFlow (Redwood City, CA, USA), GlaxoSmithKline (Brentford, UK), Novartis, Philips (Amsterdam, the Netherlands) and Siemens Healthineers AG (Erlangen, Germany). He has held grants from the National Institute for Health Research Efficacy and Mechanism Evaluation programme (reference 12/170/45) and the British Heart Foundation (reference FS/16/74/32573; RE/18/6/34217) in support of the current study.

Published November 2020
DOI: 10.3310/eme07050

Plain English summary
The T-TIME RCT
Efficacy and Mechanism Evaluation 2020; Vol. 7: No. 5
DOI: 10.3310/eme07050

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

A heart attack is usually caused by a sudden blockage in a main blood vessel that supplies the heart. The best initial treatment is to open the blocked artery as soon as possible. Nearly 50 years ago, a 'clot buster' drug was used by doctors to open the blocked heart blood vessel. The standard of care is now treatment with a stent. The procedure is called primary percutaneous coronary intervention. About half of all heart attack patients will still have reduced blood flow in the heart.

Microvascular obstruction

When small-vessel blood flow remains reduced after a heart attack, this problem is called microvascular obstruction. It is caused by the persistence of mini blood clots in the small branches of the culprit artery (which are like the tiny branches of a tree). Microvascular obstruction impairs pump function, leading to heart failure. There is no known treatment for microvascular obstruction and it is a problem of unmet need.

The T-TIME trial

The aim was to determine whether or not a mini dose of the clot-breaking drug alteplase might reduce microvascular obstruction when given directly to the culprit heart artery at the time of the stent procedure. The main outcome of the study was the amount of microvascular obstruction as revealed by magnetic resonance imaging 2–7 days after the heart attack. A double-blind design meant that the patients, doctors and researchers were unaware of the treatment received.

In total, 440 heart attack patients were enrolled from 11 NHS hospitals between 17 March 2016 and 21 December 2017. Follow-up continued up to 3 months. The average age of the patients was 60 years and 15% were women. Seventeen (4%) patients withdrew from the study and seven died, and the other patients (n = 396) remained in the study for 3 months. A total of 176 (45%) out of 396 patients were affected by microvascular obstruction. The main finding was that the amount of heart injury, as revealed by microvascular obstruction on the magnetic resonance imaging at 2–7 days after the heart attack, was not different between the three treatment groups (placebo 2.3% vs. alteplase 10 mg 2.6% vs. alteplase 20 mg 3.5% of heart muscle). After 3 months, quality of life and well-being were not different between the groups.

The results do not support giving low-dose alteplase to heart attack patients after opening the culprit heart artery. More research is needed given that microvascular obstruction is a common complication of heart attack and has no known treatment.
Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)
ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

This report

The research reported in this issue of the journal was funded by the EME programme as project number 12/170/45. The contractual start date was in November 2015. The final report began editorial review in July 2019 and was accepted for publication in January 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2020. This work was produced by McCartney et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of *Efficacy and Mechanism Evaluation* and NIHR Journals Library

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

**Professor John Powell**  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck**  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont**  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijn Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk